



SummaCare
1200 E Market St, Suite 400
Akron, OH 44305-4018
summacare.com

August 13, 2026

Dear SummaCare Provider:

As part of SummaCare's ongoing evaluation of our authorization requirements, additional procedures and services will be requiring authorization **October 12, 2026**. It will be important for you to check our website or the Plan Central portal for services requiring authorization.

Please note that if the procedure below requires authorization, pre-certification will be necessary regardless of whether the service is provided in an inpatient, outpatient, or home setting.

Below is a condensed list of some of the codes that will begin requiring prior authorization for payment. You can visit our website at <https://priorauth.myplancentral.com/home> to verify whether a specific code requires prior authorization.

Other helpful links for policies and procedures may also be found within the Utilization Management tab at <https://www.summacare.com/providers/utilization-management>

If you have any questions, please contact your Provider Support Services at 330.996.8400 or email Provider Engagement at providerengagement@summacare.com for assistance.

Thank you for your ongoing support and care for our members.

New Codes Requiring Pre-Certification through SummaCare as of 10/12/2026

Procedure Codes Requiring Pre-Certification	Description
Code	DESCRIPTION
0616U	NEUROLOGY DEMENTIA DNA MTHYLTN ALYS >30000 SITES
A2040	MICROLYTE PAINGUARD, PER SQUARE CENTIMETER
A2041	FOUNDATION DRS+ DUO, PER SQUARE CENTIMETER
A2042	FOUNDATION DRS+ SOLO, PER SQUARE CENTIMETER
A2043	BIOBRANE, PER SQUARE CENTIMETER
A2044	BIOBRANE GLOVE, EACH
A2045	NOVASHIELD OR NOVOGEN WOUND MATRIX, PER SQUARE CENTIMETER
C1607	NEUROSTIM INTEG RECHG
C7566	FUSE FINGER JOINTS W/GRAFTS
C7567	BRONCH/NEEDLE BX(S) W/ NAV
C7568	COR ANGIO W/FLOW RESRV
C7569	PTCA W/ IVUS OR OCT
C7570	COR ANGIO W/FFR & 3D MAP
C7571	PCTA W/ COR LITHOTRIP
C8010	PERCUTANEOUS PLACEMENT OF PERMANENT COMMON CAROTID EMBOLIC PROTECTION DEVICE, INCLUDING ALL SYSTEM COMPONENTS AND IMAGING GUIDANCE; BILATERAL
G0571	INTRAOP NERVE CRYOABLATION
G0680	DETECTION AND QUANTIFICATION OF CORONARY ARTERY CALCIUM AND/OR AORTIC VALVE CALCIFICATION FROM ALGORITHMIC ANALYSIS OF COMPUTED TOMOGRAPHY OF THE CHEST WITH REPORT

G0681	APPLICATION OF A PREMARKET APPROVAL (PMA), 510(K), 361 HUMAN CELLS, TISSUES OR CELLULAR AND TISSUE-BASED PRODUCTS (HCT/P) NON-SHEET FORM SKIN SUBSTITUTE FOR A WOUND SURFACE AREA UP TO 100 SQ CM; FIRST 25 SQ CM OR LESS OF WOUND SURFACE AREA
G0682	APPLICATION OF A PREMARKET APPROVAL (PMA), 510(K), 361 HUMAN CELLS, TISSUES OR CELLULAR AND TISSUE-BASED PRODUCTS (HCT/P) NON-SHEET FORM SKIN SUBSTITUTE FOR A WOUND SURFACE AREA UP TO 100 SQ CM; EACH ADDITIONAL 25 SQ CM WOUND SURFACE AREA, OR PART THEREOF (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)
G0683	APPLICATION OF A PREMARKET APPROVAL (PMA), 510(K), 361 HUMAN CELLS, TISSUES OR CELLULAR AND TISSUE-BASED PRODUCTS (HCT/P) NON-SHEET FORM SKIN SUBSTITUTE GRAFT FOR A WOUND SURFACE GREATER THAN OR EQUAL TO 100 SQ CM; FIRST 100 SQ CM WOUND SURFACE AREA, OR 1% OF BODY AREA OF INFANTS AND CHILDREN
G0684	APPLICATION OF A PREMARKET APPROVAL (PMA), 510(K), 361 HUMAN CELLS, TISSUES OR CELLULAR AND TISSUE-BASED PRODUCTS (HCT/P) NON-SHEET FORM SKIN SUBSTITUTE GRAFT FOR A WOUND SURFACE GREATER THAN OR EQUAL TO 100 SQ CM; EACH ADDITIONAL 100 SQ CM WOUND SURFACE AREA OR PART THEREOF, OR EACH ADDITIONAL 1% OF BODY AREA OF INFANTS AND CHILDREN, OR PART THEREOF (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)
G9871	BHV COUNS DM PREV, ONLN 60 M
Q4418	BIOLAB MEMBRANE WRAP FLOW, PER SQUARE CENTIMETER (ADD-ON, LIST SEPARATELY IN ADDITION TO PRIMARY PROCEDURE)
Q4419	BIOLAB MEMBRANE WRAP LITE FLOW, PER SQUARE CENTIMETER (ADD-ON, LIST SEPARATELY IN ADDITION TO PRIMARY PROCEDURE)
Q4421	BIOLAB MEMBRANE WRAP SOLO, PER SQUARE CENTIMETER (ADD-ON, LIST SEPARATELY IN ADDITION TO PRIMARY PROCEDURE)
Q4422	A/C WRAP, PER SQUARE CENTIMETER (ADD-ON, LIST SEPARATELY IN ADDITION TO PRIMARY PROCEDURE)
Q4423	BIOLAB TRI-MEMBRANE WRAP FLOW, PER SQUARE CENTIMETER (ADD-ON, LIST SEPARATELY IN ADDITION TO PRIMARY PROCEDURE)
Q4424	REVIVE FT, PER SQUARE CENTIMETER (ADD-ON, LIST SEPARATELY IN ADDITION TO PRIMARY PROCEDURE)
Q4425	REVIVE TL, PER SQUARE CENTIMETER (ADD-ON, LIST SEPARATELY IN ADDITION TO PRIMARY PROCEDURE)

Q4426	DERMABIND TL + OR DERMABIND TL X, PER SQUARE CENTIMETER (ADD-ON, LIST SEPARATELY IN ADDITION TO PRIMARY PROCEDURE)
Q4427	DERMABIND DL N OR DERMABIND DL + OR DERMABIND DL X, PER SQUARE CENTIMETER (ADD-ON, LIST SEPARATELY IN ADDITION TO PRIMARY PROCEDURE)
Q4428	DERMABIND SL N OR DERMABIND SL + OR DERMABIND SL X, PER SQUARE CENTIMETER (ADD-ON, LIST SEPARATELY IN ADDITION TO PRIMARY PROCEDURE)
Q4429	DERMABIND CH N OR DERMABIND CH X, PER SQUARE CENTIMETER (ADD-ON, LIST SEPARATELY IN ADDITION TO PRIMARY PROCEDURE)
Q4435	RENATI MEMBRANE, PER SQUARE CENTIMETER (ADD-ON, LIST SEPARATELY IN ADDITION TO PRIMARY PROCEDURE)
Q4436	RENATI AC MEMBRANE, PER SQUARE CENTIMETER (ADD-ON, LIST SEPARATELY IN ADDITION TO PRIMARY PROCEDURE)
Q4437	REVIVAL AC, PER SQUARE CENTIMETER (ADD-ON, LIST SEPARATELY IN ADDITION TO PRIMARY PROCEDURE)
Q4438	PRETECT, PER SQUARE CENTIMETER (ADD-ON, LIST SEPARATELY IN ADDITION TO PRIMARY PROCEDURE)
Q4440	CURAMATRIX, PER SQUARE CENTIMETER (ADD-ON, LIST SEPARATELY IN ADDITION TO PRIMARY PROCEDURE)
1026T	TRANSVAGINAL LASER PHOTOBIMODULATION THER PLVS
1027T	PERQ INSJ/RPLCMT NSTIM CATH VENTILATED PT
1028T	MAPG & PRGRMG NSTIM CATH VENT PT W/REPOSITIONING
1029T	MAPG & PRGRMG NSTIM CATH VENT PT W/O REPOSITIONING
1030T	CRTJ DIG 3D MDL SURF MESH FILES PT SPEC ANAT 1ST
1031T	CRTJ DIG 3D MDL SURF MESH FILES PT SPEC ANAT EA
1032T	CRTJ DIG 3D MDL SURF MESH SPEC ANAT & DIG SIM 1ST
1033T	CRTJ DIG 3D MDL SURF MESH SPEC ANAT & DIG SIM EA
1034T	CRTJ DIG 3D MDL SURF MSH ANAT DIG SIM & CMP ALYS 1
1035T	CRTJ DIG 3D MDL SRF MSH ANAT DIG SIM & CMP ALYS EA

1036T	N-INVAS HEMODYN ASSMT PULM PRS & EJECTION FRACTION
1037T	HISTOTRIPSY MAL PANCREATIC TISSUE W/IMG GDN
1038T	AUTOL MUSC CLL THER NJX MUSC PROGEN CELLS TONGUE
1039T	CONNECTOMIC ALYS PREVIOUS MULTI-MODAL BRAIN MRI
1040T	BRONCHOSCOPY FLX W/BRNCL CRTX 1 LUNG W/TRACHEA
1041T	AUGMNT ALG ALYS ENCEPH WAVFRM EPILEPTIFORM ACTV
1042T	IMPL ABSRB URO SCAFF PRSTATC URETHRA RESTORATION
1043T	QUAN MR W/O IMG ALYS LIVER TISSUE ASSMT 1/+PARAM
1044T	HRV FTH SKN AUTOL HETEROG SKIN CONSTRUCT GRF 1ST
1045T	HRV FTH SKN AUTOL HETEROG SKIN CONSTRUCT GRF EA
1046T	AUTOL HETEROG SKIN CONST GRF APPL T/A/L 1ST
1047T	AUTOL HETEROG SKIN CONST GRF APPL T/A/L EA ADDL
1048T	AUTOL HETEROG SKIN CONST GRF APPL F-DGT 1ST
1049T	AUTOL HETEROG SKIN CONST GRF APPL F-DGT EA ADDL
1050T	INSERTION SUBQ HEART FAILURE DECOMPENSATION MNTR
1051T	REMOVAL SUBQ HEART FAILURE DECOMPENSATION MNTR
1052T	INTEROG DEV EVAL SUBQ HRT FAIL DCOMP MNTR IP/REM
1053T	PRGRMG EVAL SUBQ HEART FAILURE DCOMP MNTR IP/REM
A9574	INJECTION, FERUMOXYTOL, 1 MG
C1609	VERT DEV MOTION-PRESERV
C8014	CYSTO, LITHO, W SUCT SHEATH
G0574	MGT NEW PT DEM RES CARE CMMI
G0575	MGT EST PT DEM RES CARE CMMI
G0669	ECKM OAP-INITIAL PERIOD

G0670	ECKM OAP-FOLLOW-ON PERIOD(S)
G0671	CKM OAP-INITIAL PERIOD
G0672	CKM OAP-FOLLOW-ON PERIOD(S)
G0673	MSK OAP-INITIAL PERIOD
G0674	BH OAP-INITIAL PERIOD
G0675	BH OAP-FOLLOW-ON PERIOD(S)
G0676	STD CO-MGMT-ECKM, CKM
G0677	STD CO-MGMT-MSK
G0678	STD CO-MGMT-BH
0665U	HEPATOLOGY (METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS [MASH]), ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) FOR YKL40 AND QUANTITATIVE REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (RT QPCR) FOR MIR34A-5P, SERUM, ALGORITHM REPORTED AS A SINGLE SCORE FOR MASH ACTIVITY AND FIBROSIS
0667U	INBORN ERROR OF METABOLISM (PRIMARY MITOCHONDRIAL DISEASE), DETERMINATION OF FIBROBLAST GROWTH FACTOR 21 (FGF21) CONCENTRATION BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), SERUM OR PLASMA, DIAGNOSTIC QUANTITATIVE RESULT
0692U	CARDIOLOGY (PERIPHERAL ARTERY DISEASE [PAD]), ANALYSIS OF 3 PROTEINS (MIDKINE, ANGIOPOIETIN-1, AND KIDNEY INJURY MOLECULE-1 [KIM-1]), IMMUNOASSAY, PLASMA, ALGORITHM REPORTED AS A RISK SCORE FOR OBSTRUCTIVE PAD
0694U	ONCOLOGY (MONOCLONAL GAMMOPATHY), IMMUNOPRECIPITATION AND MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF -FLIGHT (MALDI-TOF) MASS SPECTROMETRY, IDENTIFICATION OF INTACT MONOCLONAL IMMUNOGLOBULIN ISOTYPES (IGG, IGA, IGM, KAPPA, LAMBDA), AND M-PROTEIN CONCENTRATIONS IN CONJUNCTION WITH TURBIDIMETRY, BLOOD, SEMIQUANTITATIVE
0698U	NEUROLOGY (TRAUMATIC BRAIN INJURY), ANALYSIS OF GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP) AND UBIQUITIN CARBOXY-TERMINAL HYDROLASE L1 (UCHL1), IMMUNOASSAY, SERUM OR PLASMA, INDIVIDUAL COMPONENTS REPORTED WITH THE OVERALL RESULT OF POSITIVE OR NEGATIVE BASED ON THRESHOLD COMPARISON
64600	DESTRUCTION BY NEUROLYTIC AGENT, TRIGEMINAL NERVE; SUPRAORBITAL, INFRAORBITAL, MENTAL, OR INFERIOR ALVEOLAR BRANCH

64610	DESTRUCTION BY NEUROLYTIC AGENT, TRIGEMINAL NERVE; SE COND AND THIRD DIVISION BRANCHES AT FORAMEN OVALE UNDER RADIOLOGIC MONITORING
64611	CHEMODENERVATION OF PAROTID AND SUBMANDIBULAR SALIVARY GLANDS, BILATERAL
13131	REPAIR, COMPLEX, FOREHEAD, CHEEKS, CHIN, MOUTH, NECK, AXILLAE, GENITALIA, HANDS AND/OR FEET; 1.1 CM TO 2.5 CM
14040	ADJACENT TISSUE TRANSFER OR REARRANGEMENT, FOREHEAD, CHEEKS, CHIN, MOUTH, NECK, AXILLAE, GENITALIA, HANDS AND/OR FEET; DEFECT 10 SQ CM OR LESS
15120	SPLIT-THICKNESS AUTOGRAFT, FACE, SCALP, EYELIDS, MOUTH, NECK, EARS, ORBITS, GENITALIA, HANDS, FEET, AND/OR MULTIPLE DIGITS; FIRST 100 SQ CM OR LESS, OR 1% OF BODY AREA OF INFANTS AND CHILDREN
17311	MOHS MICROGRAPHIC TECHNIQUE, INCLUDING REMOVAL OF ALL GROSS TUMOR, SURGICAL EXCISION OF TISSUE SPECIMENS, MAPPING, COLOR CODING OF SPECIMENS, MICROSCOPIC EXAMINATION OF SPECIMENS BY THE SURGEON, AND HISTOPATHOLOGIC PREPARATION INCLUDING ROUTINE STAIN(S) HEAD, NECK, HANDS, FEET, GENITALIA, OR ANY LOCATION WITH SURGERY DIRECTLY INVOLVING MUSCLE, CARTILAGE, BONE, TENDON, MAJOR NERVES, OR VESSELS; FIRST STAGE, UP TO 5 TISSUE BLOCK
17312	MOHS MICROGRAPHIC TECHNIQUE, INCLUDING REMOVAL OF ALL GROSS TUMOR, SURGICAL EXCISION OF TISSUE SPECIMENS, MAPPING, COLOR CODING OF SPECIMENS, MICROSCOPIC EXAMINATION OF SPECIMENS BY THE SURGEON, AND HISTOPATHOLOGIC PREPARATION INCLUDING ROUTINE STAIN(S) HEAD, NECK, HANDS, FEET, GENITALIA, OR ANY LOCATION WITH SURGERY DIRECTLY INVOLVING MUSCLE, CARTILAGE, BONE, TENDON, MAJOR NERVES, OR VESSELS; EACH ADDITIONAL STAGE AFTER THE FIRST STAGE, UP TO 5 TISSUE BLOCK
17313	MOHS MICROGRAPHIC TECHNIQUE, INCLUDING REMOVAL OF ALL GROSS TUMOR, SURGICAL EXCISION OF TISSUE SPECIMENS, MAPPING, COLOR CODING OF SPECIMENS, MICROSCOPIC EXAMINATION OF SPECIMENS BY THE SURGEON, AND HISTOPATHOLOGIC PREPARATION INCLUDING ROUTINE STAIN(S) OF THE TRUNK, ARMS, OR LEGS; FIRST STAGE, UP TO 5 TISSUE BLOCKS
17314	MOHS MICROGRAPHIC TECHNIQUE, INCLUDING REMOVAL OF ALL GROSS TUMOR, SURGICAL EXCISION OF TISSUE SPECIMENS, MAPPING, COLOR CODING OF SPECIMENS, MICROSCOPIC EXAMINATION OF SPECIMENS BY THE SURGEON, AND HISTOPATHOLOGIC PREPARATION INCLUDING ROUTINE STAIN(S) OF THE TRUNK, ARMS, OR LEGS; EACH ADDITIONAL STAGE AFTER THE FIRST STAGE, UP TO 5 TISSUE BLOCKS
17315	MOHS MICROGRAPHIC TECHNIQUE, INCLUDING REMOVAL OF ALL GROSS TUMOR, SURGICAL EXCISION OF TISSUE SPECIMENS, MAPPING, COLOR CODING OF SPECIMENS, MICROSCOPIC EXAMINATION OF SPECIMENS BY THE

	SURGEON, AND HISTOPATHOLOGIC PREPARATION INCLUDING ROUTINE STAIN(S) (EG, HEMATOXYLIN AND EOSIN, TOLUIDINE BLUE), EACH ADDITIONAL BLOCK AFTER THE FIRST 5 TISSUE BLOCKS, ANY STAGE
G0465	AUTOLOGOUS PLATELET RICH PLASMA (PRP) OR OTHER BLOOD-DERIVED PRODUCT FOR DIABETIC CHRONIC WOUNDS/ULCERS, USING AN FDA-CLEARED DEVICE FOR THIS INDICATION
G0460	AUTOLOGOUS PLATELET RICH PLASMA OR OTHER BLOOD-DERIVED PRODUCT FOR NON-DIABETIC CHRONIC WOUNDS/ULCERS, INCLUDING AS APPLICABLE PHLEBOTOMY, CENTRIFUGATION OR MIXING, AND ALL OTHER PREPARATORY PROCEDURES, ADMINISTRATION AND DRESSINGS, PER TREATMENT
58578	UNLISTED LAPAROSCOPY PROCEDURE, UTERUS
S9988	SERVICES PROVIDED AS A PART OF A PHASE I CLINICAL TRIAL
S9990	SERVICES PROVIDED AS A PART OF A PHASE II CLINICAL TRIAL
S9991	SERVICES PROVIDED AS A PART OF A PHASE III CLINICAL TRIAL

New codes requiring pre-certification through EviCore as of 10/12/2026

0631U	ONC SOL TUM DNA SEQ ALYS 15
0632U	RBC AG FTL RHD GEN ALYS MPCR
0633U	OB 1-GENE N-INVAS PRNTL TST
0634U	ONC BRST CA CFDNA EVL 11ESR1
0635U	AI AD MRNA GENE XPRSN 487GEN
0636U	BABESIA 20 RPRTN GRPS IGG
0637U	BABESIA 20 RPRTN GRPS IGM
0638U	BARTONELLA ANTB DETCJ 32 IGM
0639U	BARTONELLA ANTB DETCJ 32 IGG
0640U	ONC LM TUMOR CELL SLCTN ID
0641U	ONC MRD TUM DNA NGS FFPE 1ST
0642U	ONC MRD TUM DNA NGS WHL BLD

0643U	ONC GU CA CFCTDNA 200GEN NGS
0644U	ONC LEUKEMIA MRD BASELINE
0645U	ONC LEUKEMIA MRD BASED DPCR
0646U	ONC MR DS CFDNA WHL BLD&FFPE
0647U	ONC MR DS WGS CFDNA CTDNA
0648U	ONC SOL TUM TGSA 42/10/18 GEN
0649U	NEURO ALZ DS DNA NGS AD 1&2
0650U	RX METAB ADVRS RXNS & RSPSE 9
0651U	ONC HERED CA 55GEN NGS DMLPA
0652U	RX METAB ADVERSE DNA ALYS 13
0653U	NFRO INH KDN DO DNA 700 GENS
0654U	IEM PMD 1NZM COMPLEX WB ALYS
0655U	IEM PMD 1NZM COMPLEX SK ASY
0656U	IEM PMD 1NZM COMPLEX RADACT
0657U	RARE DS SEQ ALYS CMPRTR NUC
0658U	RARE DS NUC&MITOCHD RL DNA
0659U	RARE DS ULTRAPID WGSALYS DNA
0660U	HUMAN PAPILLOMAVIRUS (HPV), GENOTYPES 18, 31, 33, AND 35, CELL-FREE DNA (CFDNA), WHOLE BLOOD, MULTIPLEX DIGITAL DROPLET PCR (DDPCR), QUANTITATIVE
0661U	HUMAN PAPILLOMAVIRUS (HPV), GENOTYPE 16, CELL-FREE DNA (CFDNA), WHOLE BLOOD, DIGITAL DROPLET PCR (DDPCR), QUANTITATIVE
0662U	TRANSPLANTATION MEDICINE (KIDNEY ALLOGRAFT REJECTION), MRNA, GENE-EXPRESSION PROFILING BY REAL-TIME QUANTITATIVE PCR OF 12 GENES (11 CONTENT AND 1 HOUSEKEEPING), URINE, ALGORITHM REPORTED AS A REJECTION RISK SCORE
0663U	OBSTETRICS (FETAL PLATELET ANTIGEN NONINVASIVE PRENATAL TEST [NIPT]), CELL-FREE DNA (CFDNA) SEQUENCE ANALYSIS FOR DETECTION OF FETAL PRESENCE OR ABSENCE OF 1 HUMAN PLATELET ANTIGEN OR MORE (HPA-1A,

	HPA-1B, HPA-3A, HPA-5B, AND OTHERS) WHEN PERFORMED, REPORTED AS MATERNAL/FETAL INCOMPATIBILITY DETECTED OR NOT DETECTED PER SELECTED ANTIGEN
0664U	TRANSPLANTATION MEDICINE (KIDNEY ALLOGRAFT FAILURE), RNA EXPRESSION TRANSCRIPTOME BY NEXT-GENERATION SEQUENCING (NGS), PROFILING OF 13 GENES, POST-TRANSPLANT PERIPHERAL BLOOD, ALGORITHM REPORTED AS A RISK SCORE FOR PREDICTING PROGRESSIVE FIBROSIS IN THE KIDNEY ALLOGRAFT
0668U	ONCOLOGY (PANCREAS), DNA, GENOME SEQUENCE WITH 5HYDROXYMETHYLCYTOSINE (5HMC) ENRICHMENT AND GLYCAN BIOMARKER ANALYSIS, WHOLE BLOOD OR PLASMA, ALGORITHM REPORTED AS CANCER DETECTED OR NOT DETECTED
0670U	RARE DISEASES (CONSTITUTIONAL/HERITABLE DISORDERS), WHOLE GENOME SEQUENCE ANALYSIS COMBINATION OF SHORT AND LONG READS FOR SINGLE-NUCLEOTIDE VARIANTS, INSERTIONS/DELETIONS AND CHARACTERIZED INTRONIC VARIANTS, COPY NUMBER VARIANTS, DUPLICATIONS/DELETIONS, MOBILE ELEMENT INSERTIONS, RUNS OF HOMOZYGOSITY, ANEUPLOIDY, AND INVERSIONS, MITOCHONDRIAL DNA SEQUENCE AND DELETIONS, SHORT TANDEM REPEAT (STR) GENES, METHYLATION STATUS OF SELECTED REGIONS, BLOOD, SALIVA, AMNIOCENTESIS, CHORIONIC VILLUS SAMPLE OR TISSUE, IDENTIFICATION AND CATEGORIZATION OF GENETIC VARIANT, PROBAND AND COMPARATOR
0671U	RARE DISEASES (CONSTITUTIONAL/HERITABLE DISORDERS), WHOLE GENOME SEQUENCE ANALYSIS COMBINATION OF SHORT AND LONG READS FOR SINGLE-NUCLEOTIDE VARIANTS, INSERTIONS/DELETIONS AND CHARACTERIZED INTRONIC VARIANTS, COPY NUMBER VARIANTS, DUPLICATIONS/DELETIONS, MOBILE ELEMENT INSERTIONS, RUNS OF HOMOZYGOSITY, ANEUPLOIDY, AND INVERSIONS, MITOCHONDRIAL DNA SEQUENCE AND DELETIONS, SHORT TANDEM REPEAT (STR) GENES, METHYLATION STATUS OF SELECTED REGIONS, BLOOD, SALIVA, AMNIOCENTESIS, CHORIONIC VILLUS SAMPLE OR TISSUE, IDENTIFICATION AND CATEGORIZATION OF GENETIC VARIANT, PROBAND AND 2 COMPARATORS
0672U	RARE DISEASES (CONSTITUTIONAL/HERITABLE DISORDERS), WHOLE EXOME AND MITOCHONDRIAL DNA SEQUENCE ANALYSIS, INCLUDING SMALL SEQUENCE CHANGES, DELETIONS, DUPLICATIONS, SHORT TANDEM REPEAT (STR) GENE EXPANSIONS, AND VARIANTS IN NONUNIQUELY MAPPABLE REGIONS, BLOOD OR SALIVA, IDENTIFICATION AND CATEGORIZATION OF GENETIC VARIANTS, PROBAND AND COMPARATOR
0673U	RARE DISEASES (CONSTITUTIONAL/HERITABLE DISORDERS), WHOLE EXOME AND MITOCHONDRIAL DNA SEQUENCE ANALYSIS, INCLUDING SMALL SEQUENCE CHANGES, DELETIONS, DUPLICATIONS, SHORT TANDEM REPEAT (STR) GENE EXPANSIONS, AND VARIANTS IN NONUNIQUELY MAPPABLE REGIONS, BLOOD OR SALIVA, IDENTIFICATION AND CATEGORIZATION OF GENETIC VARIANTS, PROBAND AND 2 COMPARATORS
0674U	RARE DISEASES (CONSTITUTIONAL/HERITABLE DISORDERS), WHOLE GENOME AND MITOCHONDRIAL DNA SEQUENCE ANALYSIS, INCLUDING SMALL SEQUENCE CHANGES, INSERTIONS/DELETIONS, COPY NUMBER VARIANTS, MOBILE ELEMENT

	INSERTIONS, RUNS OF HOMOZYGOSITY, ANEUPLOIDY, AND INVERSIONS, SHORT TANDEM REPEAT (STR) GENE EXPANSIONS, BLOOD, SALIVA, OR GENOMIC DNA, IDENTIFICATION AND CATEGORIZATION OF GENETIC VARIANTS, PROBAND AND COMPARATOR
0675U	RARE DISEASES (CONSTITUTIONAL/HERITABLE DISORDERS), WHOLE GENOME AND MITOCHONDRIAL DNA SEQUENCE ANALYSIS, INCLUDING SMALL SEQUENCE CHANGES, INSERTIONS/DELETIONS, COPY NUMBER VARIANTS, DUPLICATIONS/DELETIONS, MOBILE ELEMENT INSERTIONS, RUNS OF HOMOZYGOSITY, ANEUPLOIDY, AND INVERSIONS, SHORT TANDEM REPEAT (STR) GENE EXPANSIONS, BLOOD, SALIVA, OR GENOMIC DNA, IDENTIFICATION AND CATEGORIZATION OF GENETIC VARIANTS PROBAND AND 2 COMPARATORS
0676U	RARE DISEASES (CONSTITUTIONAL/HERITABLE DISORDERS), WHOLE GENOME SEQUENCE ANALYSIS, INCLUDING SMALL SEQUENCE CHANGES, COPY NUMBER VARIANTS, DELETIONS, DUPLICATIONS, MOBILE ELEMENT INSERTIONS, UNIPARENTAL DISOMY (UPD), INVERSIONS, ANEUPLOIDY, MITOCHONDRIAL GENOME SEQUENCE ANALYSIS WITH HETEROPLASMY AND LARGE DELETIONS, SHORT TANDEM REPEAT (STR) GENE EXPANSIONS AND MATERNAL CELL CONTAMINATION, FETAL SAMPLE, IDENTIFICATION AND CATEGORIZATION OF GENETIC VARIANTS, PROBAND AND MATERNAL COMPARATOR
0677U	RARE DISEASES (CONSTITUTIONAL/HERITABLE DISORDERS), WHOLE GENOME SEQUENCE ANALYSIS, INCLUDING SMALL SEQUENCE CHANGES, COPY NUMBER VARIANTS, DELETIONS, DUPLICATIONS, MOBILE ELEMENT INSERTIONS, UNIPARENTAL DISOMY (UPD), INVERSIONS, ANEUPLOIDY, MITOCHONDRIAL GENOME SEQUENCE ANALYSIS WITH HETEROPLASMY AND LARGE DELETIONS, SHORT TANDEM REPEAT (STR) GENE EXPANSIONS AND MATERNAL CELL CONTAMINATION, FETAL SAMPLE, IDENTIFICATION AND CATEGORIZATION OF GENETIC VARIANTS, PROBAND AND 2 COMPARATORS
0678U	ONCOLOGY (HEREDITARY CANCER), GENOME SEQUENCE FOR 117 GENES (SINGLE-NUCLEOTIDE VARIANTS, DELETIONS/INSERTIONS, AND CHARACTERIZED INTRONIC VARIANTS), COPY NUMBER VARIANTS, DUPLICATIONS/DELETIONS, MOBILE ELEMENT INSERTIONS AND INVERSIONS, BLOOD, SALIVA, CULTURED SKIN FIBROBLASTS (SKIN BIOPSY) OR EXTRACTED GENOMIC DNA, DIAGNOSTIC, IDENTIFICATION AND CATEGORIZATION OF GENETIC VARIANTS
0679U	ONCOLOGY (HEREDITARY HEMATOLOGIC CANCER), GENOMIC DNA, WHOLE GENOME SEQUENCE (SINGLE-NUCLEOTIDE VARIANTS, DELETIONS/INSERTIONS, AND CHARACTERIZED INTRONIC VARIANTS), COPY NUMBER VARIANTS, DUPLICATIONS/DELETIONS, MOBILE ELEMENT INSERTIONS AND INVERSIONS, ANALYSIS OF OVER 105 GENES, GENOMIC DNA ISOLATED FROM BLOOD, SALIVA, CULTURED SKIN FIBROBLASTS (SKIN BIOPSY), IDENTIFICATION AND CATEGORIZATION OF GENETIC VARIANTS
0680U	TOBACCO USE, DNA ANALYSIS OF 1 METHYLATION MARKER (CG05575921 [AHRR]), METHYLATION SENSITIVE DIGITAL PCR, WHOLE BLOOD, ALGORITHM REPORTED AS QUANTITATIVE PERCENTAGE METHYLATION AND ESTIMATED AVERAGE CIGARETTE USE PER DAY
0681U	TOBACCO USE, DNA ANALYSIS OF 2 METHYLATION MARKERS (1 CONTENT: CG05575921 [AHRR] AND 1 NORMALIZING: CG08141395), METHYLATION

	SENSITIVE DIGITAL PCR, SALIVA, ALGORITHM REPORTED AS QUANTITATIVE PERCENT METHYLATION AND ESTIMATED AVERAGE CIGARETTE USE PER DAY
0682U	ONCOLOGY (LUNG CANCER), DNA ANALYSIS OF 1 METHYLATION MARKER (CG05575921), METHYLATION-SENSITIVE DIGITAL PCR, WHOLE BLOOD, ALGORITHM RESULTS REPORTED AS THE 20 YEAR-HAZARD RATIO FOR LUNG CANCER
0683U	ONCOLOGY (LUNG CANCER), DNA ANALYSIS OF 2 METHYLATION MARKERS (1 CONTENT: CG05575921 AND 1 NORMALIZING: CG08141395), METHYLATION-SENSITIVE DIGITAL PCR, SALIVA, ALGORITHM RESULTS REPORTED AS THE 20-YEAR-HAZARD RATIO FOR LUNG CANCER
0684U	ALCOHOL USE DISORDER, DNA ANALYSIS OF 4 METHYLATION MARKERS (CG02583484, CG04987734, CG09935388, CG04583842), METHYLATION-SENSITIVE DIGITAL PCR, WHOLE BLOOD, ALGORITHM REPORTED AS A SUMMED T SCORE
0685U	ALCOHOL USE DISORDER, DNA ANALYSIS OF 5 METHYLATION MARKERS (4 CONTENT: CG02583484, CG04987734, CG09935388, CG04583842, AND 1 NORMALIZING: CG08141395), METHYLATION SENSITIVE DIGITAL PCR, WHOLE BLOOD OR SALIVA, ALGORITHM REPORTED AS A SUMMED T-SCORE
0686U	ONCOLOGY (PROSTATE), MRNA, NEXT-GENERATION SEQUENCING (NGS) GENE EXPRESSION PROFILING OF 22 GENES, FORMALIN FIXED PARAFFIN EMBEDDED (FFPE) TISSUE, ALGORITHM REPORTED AS RISK SCORE
0687U	COMPARATIVE ANALYSIS USING SHORT TANDEM REPEAT (STR) MARKERS, PATIENT AND COMPARATIVE SPECIMEN, DNA, BUCCAL SWAB AND TISSUE, REPORTED MATCH OR MISMATCH
0688U	ONCOLOGY (COLORECTAL CANCER), ANALYSIS OF MINIMAL RESIDUAL DISEASE (MRD), NEXT GENERATION SEQUENCING (NGS), CIRCULATING TUMOR DNA (CTDNA) ANALYSIS IN WHOLE BLOOD AND TUMOR FOR BASELINE ASSESSMENT TO EVALUATE CURRENT MRD STATUS AND FOR COMPARISONS TO SUBSEQUENT MRD ASSESSMENTS
0689U	ONCOLOGY (COLORECTAL CANCER), ANALYSIS OF MINIMAL RESIDUAL DISEASE (MRD) USING PATIENT-SPECIFIC ASSAYS, REPORTED AS AMOUNT OF CIRCULATING TUMOR DNA (CTDNA) DETECTION AND TREND OVER TIME
0690U	TRANSPLANTATION MEDICINE (ALLOGRAFT REJECTION), QUANTIFICATION OF DONOR-DERIVED CELL-FREE DNA (CFDNA) USING DIGITAL PCR ANALYSIS OF 45 SINGLE-NUCLEOTIDE POLYMORPHISMS, PLASMA, REPORTED AS QUANTITY OF DONOR-DERIVED CFDNA IN PLASMA TO DETERMINE THE PROBABILITY OF ALLOGRAFT REJECTION
0693U	ONCOLOGY (HEAD AND NECK), CIRCULATING TUMOR DNA (CTDNA), TUMOR-INFORMED NEXT GENERATION SEQUENCING (NGS) ANALYSIS FOR 699 GENES OF PATIENT-SPECIFIC SOMATIC VARIANTS IDENTIFIED FROM PRIMARY TUMOR TISSUE, POSTOPERATIVE LYMPHATIC EXUDATE SPECIMEN, ALGORITHM REPORTED AS PRESENCE OR ABSENCE OF CTDNA

0695U	ONCOLOGY (CENTRAL NERVOUS SYSTEM), LOW-PASS WHOLE GENOME SEQUENCE ANALYSIS OF CEREBROSPINAL FLUID, INTERROGATION FOR CHROMOSOME ARM-LEVEL AND FOCAL LOSSES AND GAINS
0696U	ONCOLOGY (SOLID ORGAN), TARGETED GENOMIC SEQUENCE ANALYSIS, FORMALIN-FIXED PARAFFIN EMBEDDED (FFPE) TUMOR TISSUE, RNA ANALYSIS, 350 OR MORE GENES FOR RNA ALTERATIONS (EG, GENE REARRANGEMENTS AND SPLICE ISOFORMS)
0697U	OBESITY, DNA GENOTYPING, ANALYSIS OF UP TO 41 GENES, BUCCAL SWAB OR BLOOD SPECIMEN, PATIENT BIOMETRICS, RISK-SCORE ALGORITHM TO IDENTIFY A PREDISPOSITION TO UP TO 4 PHENOTYPES, REPORTED AS LIKELIHOOD TO BENEFIT FROM THERAPEUTICS